Search

Insmed

Geschlossen

BrancheGesundheitswesen

123.69 -1.83

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

122.2

Max

126

Schlüsselkennzahlen

By Trading Economics

Einkommen

150M

-13M

Verkäufe

120M

425M

EPS

-0.52

Gewinnspanne

-3.112

Angestellte

1,664

EBITDA

150M

14M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+59.15% upside

Dividenden

By Acuity

Nächstes Ergebnis

29. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

8.1B

29B

Vorheriger Eröffnungskurs

125.52

Vorheriger Schlusskurs

123.69

Nachrichtenstimmung

By Acuity

40%

60%

138 / 340 Ranking in Healthcare

Insmed Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Aug. 2026, 19:36 UTC

Insmed Inc shares are lower, reflecting broader market sentiment after a reported decline in retail sales. The stock has closed lower for four consecutive sessions.

13. Aug. 2026, 19:51 UTC

News
Social Media

Insmed shares are lower despite raised earnings estimates and target price increases from HC Wainwright and Wells Fargo during Thursday's session.

12. Aug. 2026, 19:36 UTC

News

Insmed shares are trading lower despite multiple analysts issuing positive ratings and target price increases, including BMO's $192.00 and Cantor Fitzgerald's $235.00.

11. Aug. 2026, 21:16 UTC

Insmed Inc. shares moved slightly lower during after-market hours, remaining near the upper end of their one-month range and above the 20-day moving average.

10. Aug. 2026, 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

7. Aug. 2026, 21:21 UTC

Insmed Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

6. Aug. 2026, 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

5. Aug. 2026, 23:22 UTC

Insmed Inc shares are higher in after-market trading, reflecting positive momentum amid a significant drop in crude oil prices and easing inflation concerns.

3. Aug. 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31. Juli 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30. Juli 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28. Juli 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27. Juli 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24. Juli 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22. Juli 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21. Juli 2026, 17:41 UTC

Social Media
News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20. Juli 2026, 19:16 UTC

News
Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Peer-Vergleich

Kursveränderung

Insmed Prognose

Kursziel

By TipRanks

59.15% Vorteil

12-Monats-Prognose

Durchschnitt 201.06 USD  59.15%

Hoch 243 USD

Tief 169 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Insmed – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

19

Buy

0

Halten

0

Sell

Stimmung

By Acuity

138 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat